Journal of Modern OncologyJournal of Modern OncologyСовременная онкология1815-14341815-1442LLC Obyedinennaya Redaktsiya26697ArticlesСтатьиShort CommunicationTayverb/Tyverb (lapatinib) – pervyy dvoynoy anti-ErbB1(EGFR)i anti-ErbB2(HER2)-ingibitor v lechenii mestno-rasprostranennogo i metastaticheskogo raka molochnoy zhelezy zaregistrirovan v Rossiyskoy FederatsiiТайверб/Tyverb (лапатиниб) – первый двойной анти-ErbB1(EGFR)и анти-ErbB2(HER2)-ингибитор в лечении местно-распространенного и метастатического рака молочной железы зарегистрирован в Российской Федерации--15032008101NO1 (2008)ТОМ 10, №1 (2008)4609042020Copyright ©; 2008, Consilium MedicumCopyright ©; 2008, ООО "Консилиум Медикум"2008Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc/4.0https://modernonco.orscience.ru/1815-1434/article/view/26697рак молочной железылапатиниб[Saez R, Molina M.A., Ramsey E.E. et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006; 12: 424–31.][Chandarlapaty S, Scaltriti M, Baselga J et al. Extracellular cleaved HER2 (p95) confers partial resistance to trastuzumab but not HSP90 inhibitors in models of HER2 amplified breast cancer. ASCO 2007, abstr. 10515.][Blackwell K.L., Kaplan E.H., Franco S.X. et al. A phase II, open - label, multicenter study of GW572016 in patients with trastuzumab - refractory metastatic breast cancer. J Clin Oncol 2004; 22 (14 Suppl.).][Geyer C.E., Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2positive advanced breast cancer. N Engl J Med 2006; 355: 2733–43.][Sherrill B, Allshouse A, Amonkar M et al. A quality - adjusted time without symptoms or toxicity (Q-TWiST) analysis comparing lapatinib plus capecitabine compared to capecitabine for metastatic breast cancer (MBC). ASCO 2007; abstr. 1026.][Geyer C.E., Martin A, Newstat B et al. Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data. ASCO 2007, abstr. 1035.][Lin N.U., Dieras V, Paul D et al. EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). ASCO 2007; abstr. 1012.][Gomez H.L., Chavez M.A., Doval D.C. et al. A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first - line treatment in patients with FISH positive advanced or metastatic breast cancer. SABCS 2006; abstr. 1090.][Di Leo A, Gomez H, Aziz Z et al. Lapatinib (L) with paclitaxel compared to paclitaxel as first - line treatment for patients with metastatic breast cancer: A phase III randomized, double - blind study of 580 patients. ASCO 2007; abstr. 1011.][Cristofanilli M, Boussen H, Baselga J. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer. Breast Cancer Res 2006; 100 (Suppl. 1): S5.][Crown J.P., Burris H.A., Jones S et al. Safety and tolerability of lapatinib in combination with taxanes (T) in patients with breast cancer (BC). ASCO 2007; abstr. 1027.][Семиглазов В.Ф., Иванов В.Г., Семиглазов В.В. и др. Биологически направленная терапия рака молочной железы. Рус. мед. журн. (Онкология). 2007;(15): 1912–4.][Жукова Л.Г., Личиницер М.Р. Лапатиниб – ингибитор тирозинкиназ EGFR и HER2. Новые перспективы лечения больных с HER2 положительными опухолями. По материалам ASCO-2007. Фарматека, Онкология ASCO-2007; 18–23.]